Krystal Biotech, Inc. (KRYS)

171,37 -1,63 (-0,95%) Ab 11:09AM EDT. Markt geöffnet.

Krystal Biotech, Inc.

2100 Wharton Street
Suite 701
Pittsburgh, PA 15203
United States
412 586 5830
https://www.krystalbio.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 229

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Krish S. Krishnan M.B.A., M.S.	Founder, Chairman, President & CEO	1,32M	N/A	1965
Ms. Suma M. Krishnan	Founder, President of R&D and Director	895,33k	N/A	1965
Ms. Kathryn A. Romano	Executive VP & Chief Accounting Officer	614,87k	2,35M	1982
Mr. John Thomas	General Counsel & Corporate Secretary	N/A	N/A	N/A
Mr. John Karakkal	Vice President of North American Sales & Marketing	N/A	N/A	N/A
Ms. Christine Wilson	Head of U.S. Sales and Marketing	N/A	N/A	N/A
Dr. Stephane Paquette Ph.D.	Vice President of Corporate Development	N/A	N/A	N/A
Mr. Josh Suskin	Director of Human Resources & Operations	N/A	N/A	N/A
Mr. Laurent Goux	Senior VP & GM of Europe	N/A	N/A	N/A
Mr. David Chien	Senior Vice President of Clinical Development	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Corporate Governance

Krystal Biotech, Inc.s ISS Governance QualityScore, Stand 1. Juni 2024, lautet 7. Die grundlegenden Scores sind Audit: 3, Vorstand: 9, Shareholderrechte: 8, Kompensation: 5.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.